F Poizeau,S Leducq,L Fardet,M Beylot-Barry,Guillaume Chaby,M Chastagner,F Corgibet,L Gouillon,N Jouan,D Jullien,A Acher,F Amatore,J-M Amici,H Aubert,F Aubin,N Beneton,D Bouilly,A-C Bursztejn,C Buzenet,M Chamaillard-Pujol,J Charles,A-C Cottencin-Charriere,B Duval Modeste,A Fauconneau,A-C Fougerousse,C Girard,C Goujon,A Khemis,Y Le Ru,C Lepelley-Dupont,E Mahé,X Marcellin,C Nicolas,V Pallure,J Parier,N Quiles,P-E Stoebner,M Tauber,A Vermersch,M Viguier,A P Villani,O Chosidow,B Guillot,Psoriasis Research Group (GRPso) and the Centre of Evidence of the French Society of Dermatology

Abstract:Background: New highly effective drugs for moderate-to-severe cutaneous psoriasis are regularly marketed, and the hierarchy of treatments thus requires frequent review. Objectives: A Delphi method was used to enable a structured expert consensus on the use of systemic treatments and phototherapy among adults with moderate-to-severe psoriasis. Methods: The Delphi method consists in achieving a convergence of opinions among a panel of experts using several rounds of questionnaires with controlled feedback between rounds. A two-part Delphi questionnaire was administered online to French psoriasis experts. In the first part, 180 items related to the prescription of systemic treatments and phototherapy for adult patients with moderate-to-severe psoriasis were grouped into 21 sections covering different lines of treatment and different forms of cutaneous psoriasis. The experts voted on each proposal using an ordinal 7-point Likert scale. The second part comprised 11 open-ended questions about special indications for each therapeutic class. These were converted into 101 questions for subsequent rounds. Consensus was deemed to have been reached if more than 80% of the experts agreed with a given proposal. Results: Three rounds of questionnaires were sequentially sent to 35 participants between November 2021 and March 2022. Thirty-three (94%) completed all three rounds. For plaque psoriasis, only methotrexate was recommended by the experts as first-line systemic treatment (89% of votes). Cyclosporin was advocated in pustular and erythrodermic psoriasis, and acitretin was suggested for hyperkeratotic and palmoplantar psoriasis. In the event of failure of or intolerance to non-biological systemic treatments, guselkumab, risankizumab, ixekizumab or secukinumab were recommended by more than 80% of the experts. Tumor Necrosis Factor (TNF) inhibitors remain useful for patients with cardiovascular risk factors. Special indications were provided for each therapeutic class (methotrexate/narrowband ultraviolet B phototherapy, psoralen/ultraviolet A phototherapy, cyclosporin, acitretin, apremilast, TNF inhibitors, interleukin (IL)-12/23 inhibitors, IL-17(R)A inhibitors, and IL-23 inhibitors). Conclusions: This expert consensus statement indicate that newly available IL-17 and IL-23 inhibitors may be favored over TNF and IL-12/23 inhibitors as first-line biologics. The Centre of Evidence of the French Society of Dermatology has drawn up a decision-making algorithm to guide clinicians in the therapeutic management of moderate-to-severe psoriasis.

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

Expert Consensus on the Treat-to-target Strategy for Psoriasis with Biological Agents in China

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

European S3-guidelines on the systemic treatment of psoriasis vulgaris

S3 guideline Atopic dermatitis: Part 2 - Systemic treatment

Update “Systemic treatment of atopic dermatitis” of the S2k‐guideline on atopic dermatitis

S3 Guideline Atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groups

Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm

Barriers and suggestions for improving the implementation of guidelines in the systemic treatment of moderate to severe psoriasis: A literature review

Chinese Experts Consensus on Biologic Therapy for Psoriasis #

2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Asian Consensus on Assessment and Management of Mild to Moderate Plaque Psoriasis with Topical Therapy.

Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II)

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

Belgian recommendations for managing psoriasis in a changing treatment landscape

Review of safety and efficacy of approved systemic psoriasis therapies

Interpretation of the Latest Guidelines for the Diagnosis and the Treatment of Psoriasis at Home and Abroad:The Assessment of Disease Severity and the Treatment with Biological Agents

Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists